Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TLK-199 (Telik).

David Hamilton1, Gerald Batist

  • 1Sir Mortimer B Davis-Jewish General Hospital, Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada.

Idrugs : the Investigational Drugs Journal
|July 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized Controlled Trial of the Meaning-Making Intervention (MMi) in Patients Newly Diagnosed With Advanced Cancer: Full Trial.

Psycho-oncology·2026
Same author

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Advances in therapy·2026
Same author

Direct culture is as sensitive as bioassay to achieve in vitro isolation of Toxoplasma gondii from latently infected animal hearts.

Methods (San Diego, Calif.)·2026
Same author

Multi-perspective views about healthcare experiences for those with incurable head and neck cancer: A prospective, longitudinal, qualitative study.

Palliative medicine·2026
Same author

Surgical Contributions to Anatomical Knowledge.

Advances in anatomy, embryology, and cell biology·2026
Same author

A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer.

Cancer immunology, immunotherapy : CII·2026
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Telik Inc. is developing TLK-199, an intravenous glutathione S-transferase P1-1 inhibitor, to potentially prevent myelosuppression in blood diseases like myelodysplastic syndrome.

Area of Science:

  • Pharmacology
  • Hematology
  • Oncology

Background:

  • Myelosuppression is a significant side effect of various treatments for blood diseases.
  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and increased risk of transformation to acute myeloid leukemia.
  • Glutathione S-transferase P1-1 (GSTP1-1) is implicated in cellular protection mechanisms.

Purpose of the Study:

  • To evaluate TLK-199 as a potential therapeutic agent for preventing myelosuppression.
  • To investigate the role of glutathione S-transferase P1-1 inhibition in mitigating chemotherapy-induced or disease-related bone marrow suppression.

Main Methods:

  • TLK-199 is an intravenously administered inhibitor targeting glutathione S-transferase P1-1.

Related Experiment Videos

  • Preclinical studies and/or clinical trials are likely employed to assess efficacy and safety.
  • Pharmacokinetic and pharmacodynamic studies would be conducted.

    • Main Results:

    • Results are pending or not detailed in the provided abstract.
    • The abstract suggests a potential for TLK-199 to prevent myelosuppression.

    Conclusions:

    • TLK-199 shows promise as a novel therapeutic strategy for managing myelosuppression in hematologic malignancies.
    • Further research and clinical trials are necessary to confirm the efficacy and safety of TLK-199 for myelodysplastic syndrome and other blood diseases.